Has the MHRA stated a position on unregulated peptides
M.FitchettD.BluhmkiE.HantelS.et al (2015)
The SELECT trial, published in the New England Journal of Medicine , found that semaglutide, known by the brand name Ozempic, significantly reduced the risk of heart attacks and strokes in people with obesity and established cardiovascular disease
Dosage adjustment considerations Several factors, such as an individuals body mass index (BMI), metabolism, body response to the medication, and comorbidities, can influence medication dosage and its effectiveness
Acute pancreatitis has been reported in association with DPP-4 inhibitors [98], but a causal relationship has not been established [99,100]
However, comparing semaglutide to tirzepatide reveals that both compounds still benefit from refrigerated storage